DUBLIN, Aug 1, 2018 /PRNewswire/ --
The "Structural Heart Devices Global Market - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The structural heart device market is expected to grow at a medium double digit CAGR to reach $15,671 million by 2024.
Structural heart devices has emerged as a new focus area of medical device manufacturers as the population of most developed and developing countries continue to become older and risk of cardiovascular diseases increase with aging. The cardiovascular diseases which also include structural heart diseases have become leading cause of death.
It is projected that, with newfound prosperity due to globalization and industrialization has led to changing lifestyle leading to increasing risk of younger people developing cardiovascular diseases.
The increased interest has led to development of new technologies and devices that are less invasive and address the need of treatment of patients who are considered too weak to withstand the trauma of an open heart surgery.
The structural heart device market is classified based on product, product type and geography. Structural heart devices by product are segmented into Repair devices and Replacement devices. Repair devices by product type is segmented into Surgical Heart Repair (Annuloplasty) and Transcatheter heart repair devices. Transcatheter heart repair devices are further classified as Valvuloplasty, Occluders, Transcatheter Mitral Valve Repair and Others (Chordal replacement in mitral valve repair, Transcatheter tricuspid valve repair and Ventricular remodelling). Replacement devices by product type are segmented into Surgical Valve Replacement and Transcatheter Valve Replacement. Surgical valve replacement devices are further sub-segmented into Mechanical valves and Tissue valves. Transcatheter Valve Replacement devices are sub-segmented into Transcatheter aortic valve replacement (TAVR), Transcatheter Mitral valve replacement (TMVR), Transcatheter pulmonary valve replacement (TPVR).
Structural heart devices by product are segmented into Repair devices and Replacement devices. The replacement devices segment held the largest market revenue in 2017 and expected to grow at a medium double digit CAGR from 2017 to 2024.
In structural heart repair devices segment, transcatheter repair device held the largest share in 2017 and is projected to grow at a strong double digit CAGR from 2017 to 2024.
Among transcatheter repair devices, Transcatheter mitral valve repair device held the largest share in 2017 and is projected to grow at a strong double digit CAGR from 2017 to 2024.
The Structural heart Replacement segment is dominated by Transcatheter valve replacement that held largest share in 2017 and expected to grow at a strong double digit CAGR from 2017 to 2024.
Among the Surgical valve replacement devices, Tissue valves held the largest share in 2017 and is expected to grow at a single digit CAGR from 2017 to 2024.
Among the Transcatheter valve replacement devices, Transcatheter Aortic Valve Replacement (TAVR) devices held the largest share and expected to grow at a medium double digit CAGR from 2017 to 2024 and Transcatheter Mitral Valve Replacement (TMVR) devices is expected to grow at a strong double digit CAGR from 2017 to 2024.
The structural eart devices market by geography is divided into North America (U.S., Others), Europe (Germany, Italy, France, Others), Asia-pacific (Japan, China, Korea, Others) and Rest of the World (Brazil, Rest of Latin America, Middle East and Others).
North America region held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024. Among North America countries, U.S. held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024.
Europe held the second largest share and is expected to grow at a medium double digit CAGR from 2017 to 2024. Among European countries, Germany held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024.
Asia-Pacific is expected to grow at a strong double digit CAGR from 2017 to 2024. Among APAC countries, Japan held the highest share in 2017 and is expected to grow at a strong double digit CAGR from 2017 to 2024.
RoW is expected to grow at a medium double digit CAGR from 2017 to 2024. Among RoW countries, Brazil held the largest share in 2017 and is expected to grow at a medium double digit CAGR from 2017 to 2024.
Some of the major players in structural heart devices market include Abbott laboratories (U.S.), Medtronic (Ireland), Boston Scientific (U.S.), Edward Lifesciences (U.S.), LivaNova (U.K.), Lepu Medicals (China), JenaValve Technologies GmbH (Germany), Braile biomedia (Brazil), Cryolife (U.S.), Labcore Laboratories Ltd (Brazil).
- Abbott Laboratories
- Balton Sp. z o.o.
- Bard Peripheral Vascular, Inc.
- Biostable Science and Engineering
- BioVentrix, Inc.
- BOSTON Scientific
- Braile bio medica
- Cardiac Dimensions, Inc.
- Cardiokinetix, Inc.
- Cardiosolutions, Inc
- Cephea valve technologies
- Claret Medical
- Colibri Heart Valve, LLC
- Comed BV
- Cook medicals LLC
- Cryo life, Inc.
- Edward Lifescieces
- Effluent medical
- Guided Delivery Systems, Inc.
- Hancock Jaffe
- Heart Leaflet Technologies
- High Life medicals
- InterValve, Inc.
- JC Medicals
- JenaValve Technology GmbH
- Labcor Laboratrios Ltda.
- Leman Cardiovascular
- Lepu medical
- LivaNova PLC
- Mardil Medicals
- Medtentia International Ltd Oy
- Medtronic PLC
- MiCardia Corporation
- Micro Interventional Devices
- NaviGate Cardiac Structures Inc.
- Novostia SA
- NuMED, Inc.
- NVT Med AG
- Osypka AG
- Secant Medical
- Strait access technologies Pvt Ltd
- The Phoenix Cardiac device Pvt Ltd
- Thubrikar Aortic Valve, Inc.
- Toray Industries, Inc.
- TransCardiac Therapeutics, LLC
- Transcatheter Technologies GmbH
- TTKChitra HeartValve
- Valcare Medical
- Venus Medtech (Hangzhou) Inc.
- W. L. Gore and Associates
- Xuzhou Yatai Scientific Co. Ltd.
Key Topics Covered
1 Executive Summary
2.1 Key Takeaways
2.2 Scope Of The Report
2.3 Report Description
2.4 Markets Covered
2.6 Research Methodology
2.6.1 Market Size Estimation
2.6.2 Market Breakdown And Data Triangulation
2.6.3 Secondary Sources
2.6.4 Primary Sources
2.6.5 Key Data Points From Secondary Sources
2.6.6 Key Data Points From Primary Sources
3 Market Analysis
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
184.108.40.206 Increase In Minimally Invasive Surgery For Structural Heart Diseases
220.127.116.11 Technology Advancements And Growing Healthcare Budgetary Allocation
18.104.22.168 Rising Geriatric Population With Structural Heart Diseases
22.214.171.124 Acquisitions To Open An Array Of Opportunities For The Market To Flourish
126.96.36.199 Vast Pipeline Products
3.3.2 Restraints And Threats
188.8.131.52 High Cost Of The Structural Heart Devices
184.108.40.206 Lack Of Patient Awareness And Healthcare Infrastructure In Developing Countries
220.127.116.11 Stringent Regulatory Guidelines
18.104.22.168 Lack Of Skilled And Trained Professionals
3.4 Regulatory Affairs
3.4.1 International Organization For Standardization
22.214.171.124 Iso 9001: 2015 Quality Management System
126.96.36.199 Iso 13485 Medical Devices
188.8.131.52 Iso 10993 Biological Evaluation Of Medical Devices
3.5 Reimbursement Scenario
3.5.1 Reimbursement Table
3.6 Patent Trends
3.7 Technological Advancements
3.7.2 Tissue Engineering
3.7.3 Polymeric Heart Valves
3.7.4 Sutureless Aortic Valve Replacement (SU-AVR) System
3.7.5 Endoscopic Aortic Valve Replacement (TEVAR) System
3.7.6 3-D Printed Model
3.8 Clinical Trials
3.9 Porter'S Five Force Analysis
3.9.1 Threat Of New Entrants
3.9.2 Threat Of Substitutes
3.9.3 Bargaining Power Of Suppliers
3.9.4 Bargaining Power Of Buyers
3.9.5 Competitive Rivalry
3.10 Supply Chain Analysis
3.11 Market Share Analysis By Major Players
3.11.1 Structural Heart Devices Global Market Share Analysis
3.11.2 Market Share Analysis Of Annuloplasty Repair Devices By Major Players
3.11.3 Market Share Analysis Of Occluders By Major Players
3.11.4 Market Share Analysis Of Mechanical Valve Replacement Devices By Major Players
3.11.5 Market Share Analysis Of Tissue Valve Replacement Devices By Major Players
3.11.6 Market Share Analysis Of Transcatheter Aortic Valve Replacement By Major Players
3.12 Structural Heart Diseases U.S. Market Penetration, Prevalence, Opportunity And Number Of Procedures Performed
3.13 Structural Heart Devices Number Of Units By Region
3.13.1 Occluders Number Of Units By Region
3.13.2 Transcatheter Mitral Valve Repair Devices Number Of Units By Region
3.13.3 Surgical Valve Repari - Annuloplasty Devices Number Of Units By Region
3.13.4 Transcatheter Aortic Valve Replacement (TAVR) Devices Number Of Units By Region
3.13.5 Transcatheter Mitral Valve Replacement (TMVR) Devices Number Of Units By Region
3.13.6 Transcatheter Pulmonary Valve Replacement (TPVR) Devices Number Of Units By Region
3.14 Structural Heart Devices Company Comparison Table By Products
3.14.1 Aortic Valve Devices Company Comparison Table By Products
3.14.2 Mitral Valve Devices Company Comparison Table By Products
3.14.3 Closure Devices (Occluders) Company Comparison Table By Products
3.14.4 Other Structural Heart Devices Company Comparison Table By Products
4 Structural Heart Devices Global Market, By Product
4.2 Structural Heart Repair Devices
4.2.1 Surgical Heart Repair (Annuloplasty)
4.2.2 Transcatheter Heart Repair Devices
184.108.40.206 Transcatheter Mitral Valve Repair
220.127.116.11 Other Transcatheter Repair Devices
4.3 Structural Heart Valve Replacement Devices
4.3.2 Surgical Valve Replacement Devices
18.104.22.168 Mechanical Heart Valves
22.214.171.124 Tissue Heart Valves (Biological Valves)
4.3.3 Transcatheter Valve Replacement Devices
126.96.36.199 Transcatheter Aortic Valve Replacement (TAVR)
188.8.131.52 Transcatheter Mitral Valve Replacement (TMVR)
184.108.40.206 Transcatheter Pulmonary Valve Replacement (TPVR)
5 Regional Analysis
5.2 North America
5.5.2 Rest Of Latam
5.5.3 Middle East & Others
6 Competitive Landscape
6.4 New Product Launch
6.6 Other Developments
7 Major Companies
7.1 Abbott Laboratories
7.1.3 Product Portfolio
7.1.4 Key Developments
7.1.5 Business Strategy
7.1.6 Swot Analysis
7.2 Boston Scientific Corpoartion
7.2.3 Product Portfolio
7.2.4 Key Developments
7.2.5 Business Strategy
7.2.6 Swot Analysis
7.3 Braile Biomedica
7.3.3 Product Portfolio
7.3.4 Key Developments
7.3.5 Business Strategy
7.3.6 Swot Analysis
7.4 Cryolife, Inc.
7.4.3 Product Portfolio
7.4.4 Key Developments
7.4.5 Business Strategy
7.4.6 Swot Analysis
7.5 Edwards Lifesciences Corp.
7.5.3 Product Portfolio
7.5.4 Key Developments
7.5.5 Business Strategy
7.5.6 Swot Analysis
7.6 Jenavalve Technology
7.6.3 Product Portfolio
7.6.4 Key Developments
7.6.5 Business Strategy
7.6.6 Swot Analysis
7.7 Labcor Laboratorios Ltda.
7.7.3 Product Portfolio
7.7.4 Key Developments
7.7.5 Business Strategy
7.7.6 Swot Analysis
7.8 Lepu Medical Technology (Beijing) Co., Ltd.
7.8.3 Product Portfolio
7.8.4 Key Developments
7.8.5 Business Strategy
7.8.6 Swot Analysis
7.9 Livanova Plc (Sorin Group)
7.9.3 Product Portfolio
7.9.4 Key Developments
7.9.5 Business Strategy
7.9.6 Swot Analysis
7.10 Medtronic, Plc
7.10.3 Product Portfolio
7.10.4 Key Developments
7.10.5 Business Strategy
7.10.6 Swot Analysis
For more information about this report visit https://www.researchandmarkets.com/research/5n52x3/global_structural?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets